Literature DB >> 2838573

Analysis of the L1 gene product of human papillomavirus type 16 by expression in a vaccinia virus recombinant.

H M Browne1, M J Churcher, M A Stanley, G L Smith, A C Minson.   

Abstract

The L1 open reading frame of human papillomavirus type 16 (HPV16) has been expressed in vaccinia virus under the control of both the 7.5K early and late promoter, and the 4b major late promoter. Antibodies to a beta-galactosidase fusion protein containing a C-terminal portion of the HPV16 L1 gene product were used to compare the levels of L1 expression in the two recombinants, and showed that greater levels of expression were obtained when the gene was placed under the control of the 4b late promoter. Immunofluorescence studies revealed a nuclear location of the L1 gene product when expressed in vaccinia virus. Antibodies to the beta-galactosidase fusion protein detected a major polypeptide species of 57K and a minor species of 64K in Western blots of recombinant-infected cell lysates. The 64K species was not detected when cells were infected in the presence of tunicamycin, indicating that the primary translation product of the HPV16 L1 open reading frame is modified by N-linked glycosylation when expressed in vaccinia virus. Whereas antibodies to HPV16 L1 fusion proteins and to a peptide containing amino acids from the C terminus of HPV16 L1 reacted well in Western blots with the HPV16 L1 target expressed in vaccinia virus, no reactivity was observed with antibodies to bovine papillomavirus type 1 particles or to a HPV6b fusion protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838573     DOI: 10.1099/0022-1317-69-6-1263

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Inhibitory cis-element-mediated decay of human papillomavirus type 16 L1-transcript in undifferentiated cells.

Authors:  Seiichiro Mori; Saori Ozaki; Toshiharu Yasugi; Hiroyuki Yoshikawa; Yuji Taketani; Tadahito Kanda
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

Review 2.  Cancer of the cervix: prospects for immunological control.

Authors:  D H Davies; G A McIndoe; B M Chain
Journal:  Int J Exp Pathol       Date:  1991-04       Impact factor: 1.925

3.  Study of infectious virus production from HPV18/16 capsid chimeras.

Authors:  Horng-Shen Chen; Jennifer Bromberg-White; Michael J Conway; Samina Alam; Craig Meyers
Journal:  Virology       Date:  2010-07-03       Impact factor: 3.616

4.  A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes.

Authors:  R W Tindle; G J Fernando; J C Sterling; I H Frazer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

5.  Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus.

Authors:  C S McLean; M J Churcher; J Meinke; G L Smith; G Higgins; M Stanley; A C Minson
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

Review 6.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

7.  Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter.

Authors:  F C Mariz; E C Coimbra; A L S Jesus; L M Nascimento; F A G Torres; A C Freitas
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

8.  Expression and cellular localisation of porcine transmissible gastroenteritis virus N and M proteins by recombinant vaccinia viruses.

Authors:  D J Pulford; P Britton
Journal:  Virus Res       Date:  1991-03       Impact factor: 3.303

9.  Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein.

Authors:  Elizabeth Webb; John Cox; Stirling Edwards
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.198

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.